We evaluated the antagonistic activity of PCG in human skin-derived cell lines, followed by in vivo assessment of its effects in a PAR2-activating peptide (PAR2-AP)-induced pruritus model and a 2,4-dinitrofluorobenzene (DNFB)-induced atopic dermatitis model. This evidence concerns the gene F2RL1 and atopic eczema.